Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
62 Ocd Trials Near You
Power is an online platform that helps thousands of Ocd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerMACI vs Microfracture for Knee Cartilage Injury
Columbus, Ohio
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17
Key Eligibility Criteria
Disqualifiers:Rheumatoid Arthritis, Metabolic Bone Disease, Psoriasis, Others
45 Participants Needed
Long-Term Safety of Troriluzole for OCD
Beavercreek, Ohio
This trial is testing the safety and tolerability of troriluzole as an additional treatment for people with OCD. Troriluzole may help balance brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has been studied for its potential benefits in treating anxiety disorders and OCD.
Stay on current meds
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Acute Suicidality, Self Injurious Behavior, Others
1200 Participants Needed
Adjunctive Troriluzole for OCD
Dayton, Ohio
This trial is testing a new medication called troriluzole to see if it helps people with OCD who aren't getting enough relief from their current treatments. Troriluzole is added to their existing medications and works by changing brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has shown benefits in treating OCD when used alongside existing treatments.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
700 Participants Needed
Troriluzole for Obsessive-Compulsive Disorder
Dayton, Ohio
This trial is testing troriluzole to see if it can help people with OCD who haven't improved with common medications. Troriluzole works by balancing brain chemicals that may be causing OCD symptoms. The goal is to find a more effective treatment for those who need additional help.
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Eating Disorders, Others
Must Be Taking:SSRIs, Clomipramine, Venlafaxine
426 Participants Needed
Emotion Regulation Strategies for Emotional Regulation Issues
Lexington, Kentucky
This trial is testing whether different emotion management techniques help people reduce their negative emotions more effectively. It aims to find out which method works best for improving emotional well-being.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Non-English, No Smartphone, Others
390 Participants Needed
Osteochondral Allografts for Knee Defects
Lexington, Kentucky
The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 60
Key Eligibility Criteria
Disqualifiers:Obesity, Cancer, Infections, Others
Must Not Be Taking:Corticosteroids, Hyaluronic Acid
68 Participants Needed
Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder
Pittsburgh, Pennsylvania
This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death.
The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure and response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort.
In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation (DBS) remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment.
This current research protocol will focus on the completion of Phase II which will implant the RC+S system with ECoG paddles in 5 subjects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Psychotic Disorders, Substance Abuse, Others
Must Be Taking:SSRIs, Antipsychotics
5 Participants Needed
Deep Brain Stimulation for Obsessive-Compulsive Disorder
Pittsburgh, Pennsylvania
This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death.
The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort.
In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed deep brain stimulation may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment.
This current research protocol will focus on the completion of Phase Ib which will implant the RC+S system in 2 subjects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 70
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Substance Abuse, Neurological Disorders, Others
Must Be Taking:SSRIs, Antipsychotics
3 Participants Needed
Adaptive DBS for Obsessive-Compulsive Disorder
Pittsburgh, Pennsylvania
This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and distressing thoughts (obsessions) and irresistible repetitive behaviors. OCD affects 2-3% of the US population, and is responsible for substantial functional impairment and increased risk of early death.
The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and certain medications. About 30-40% of patients fail to respond and few experience complete symptom resolution. Up to 25% of patients have difficulty tolerating CBT and the risk of relapse after therapies remains large. For the most severe cases, neurosurgery (surgery in the brain), has long been the option of last resort.
In this study the investigators want develop an adaptive Deep Brain Stimulation (aDBS) system to use in subjects with intractable (hard to control) OCD. Deep brain stimulation remains investigational for OCD patients and is not considered standard therapy. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed deep brain stimulation may restore balance to dysfunctional brain circuitry implicated in OCD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for OCD treatment.
Phase Ia is to gather data to eventually develop a prototype adaptive DBS system for intractable OCD that uses signals from the brain to automatically adjust the DBS stimulation factors. The overall goal is to improve symptom management and reduce stimulation-induced behavioral side effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 70
Key Eligibility Criteria
Disqualifiers:Psychotic Disorders, Substance Abuse, Neurological Conditions, Others
Must Be Taking:SSRIs, Antipsychotics
2 Participants Needed
Transcranial Magnetic Stimulation + Habit Training for Compulsive Behavior
Pittsburgh, Pennsylvania
This trial uses a device that sends mild electrical signals to the brain and combines it with computer exercises. It aims to help people who have trouble controlling repetitive behaviors. The goal is to change brain activity and improve control over these behaviors.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Epilepsy, Pregnancy, Bipolar, Others
Must Not Be Taking:Clozapine, Stimulants
200 Participants Needed
This trial will test a therapy called ERP, which helps people face their fears and stop doing habits that make them feel temporarily better but keep the problem going. It will focus on Veterans with OCD, including those who also have PTSD. The goal is to see if this therapy improves their daily functioning and quality of life.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Psychosis, Mania, Others
160 Participants Needed
Tolcapone for Obsessive-Compulsive Disorder
Chicago, Illinois
This trial is testing tolcapone, a medication that may help reduce symptoms of OCD by affecting dopamine levels in the brain. It targets adults with moderate to severe OCD who have significant symptoms. The study also looks at how tolcapone might improve thinking skills and whether genetic differences affect its effectiveness. Tolcapone has been investigated for its potential cognitive benefits in healthy adults.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Psychosis, Bipolar, Substance Use, Others
Must Not Be Taking:New Psychotropics
85 Participants Needed
Cannabidiol for Obsessive-Compulsive Disorder
Chicago, Illinois
This trial aims to test if Epidiolex can safely and effectively reduce symptoms in adults with obsessive-compulsive and related disorders by calming the brain and reducing anxiety. Epidiolex is a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) that has been previously studied for its potential to be misused.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Unstable Illness, Pregnancy, Suicide Risk, Others
Must Not Be Taking:Psychotropic Medications
4 Participants Needed
Mindfulness-Based Interventions for Obsessive-Compulsive Disorder
Hamilton, Ontario
This trial is testing a new treatment called Mindfulness-Based Cognitive Therapy (MBCT) for people with Obsessive-Compulsive Disorder (OCD) who haven't fully benefited from standard treatments. MBCT helps patients become more aware of their thoughts and feelings without reacting to them, which can reduce OCD symptoms. If successful, this approach could be used widely in clinical settings to help more people with OCD. Mindfulness-Based Cognitive Therapy (MBCT) has been shown to be effective in various mental disorders and is now being explored as a complementary treatment for OCD, particularly for those who do not fully benefit from standard treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Severe Mood Disorder, Schizophrenia, Substance Abuse, Others
Must Be Taking:OCD Medications
420 Participants Needed
Troriluzole for Obsessive-Compulsive Disorder
Naperville, Illinois
This trial is testing troriluzole as an extra treatment for people with OCD. It aims to see if the medication can help by balancing brain chemicals, making other treatments work better.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
700 Participants Needed
Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard first-line treatment for obsessive-compulsive disorder (OCD). Because CBT is a psychological treatment that aims to change patterns of thinking and behaving, it may be that improvement in cognitive functioning before treatment starts could lead CBT to be even more effective. One area of research that has shown potential benefit for OCD sufferers is rTMS. rTMS is a non-invasive procedure that uses pulses of energy to stimulate regions of the brain. Brief treatment with rTMS has shown to improve attention, memory, and other aspects of cognitive functioning that may facilitate learning in CBT. The proposed study aims to provide a pilot test of the clinical effectiveness of adding brief rTMS prior to completing CBT for OCD. If rTMS can demonstrate enhancement of cognitive functioning, which in turn, can improve treatment response to CBT, then the findings could easily be translated into routine clinical care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Severe Mood Disorder, Schizophrenia, Substance Abuse, Others
Must Be Taking:OCD Medications
10 Participants Needed
Psilocybin for OCD
Toronto, Ontario
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD).
The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Substance Use Disorder, Schizophrenia, Others
Must Not Be Taking:Anticonvulsants, Benzodiazepines
10 Participants Needed
rTMS for Obsessive-Compulsive Disorder
Toronto, Ontario
This trial aims to obtain initial evidence about the clinical efficacy and modulation of neurophysiological markers in obsessive compulsive disorder (OCD) using personalized (i.e., electroencephalography (EEG)-triggered) repetitive transcranial magnetic stimulation (rTMS) as compared to non-personalized (i.e., non-EEG triggered), standard rTMS applied to the dorsomedial prefrontal cortex.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Seizures, Others
Must Be Taking:SSRIs
48 Participants Needed
Cognitive Bias Modification for Obsessive-Compulsive Disorder
Milwaukee, Wisconsin
Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., "My mother will get into a car accident, because I thought about it"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Visual Impairment, Bipolar, Psychotic, Others
84 Participants Needed
Response Inhibition Training for Obsessive-Compulsive Disorder
Milwaukee, Wisconsin
This trial tests a computer-based training program to help people with OCD, hair-pulling, and skin-picking disorders improve their self-control. The training aims to strengthen brain areas that help stop inappropriate actions, potentially reducing symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Substance Use, Severe ADHD, Psychotic, Others
Must Not Be Taking:Stimulants, Psychotropics
118 Participants Needed
Why Other Patients Applied
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
Psilocybin for OCD
Baltimore, Maryland
This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:21 - 70
Key Eligibility Criteria
Disqualifiers:Cardiovascular Conditions, Epilepsy, Type 1 Diabetes, Others
Must Not Be Taking:Psychoactive, Serotonergic, MAOIs
30 Participants Needed
Personalized Assessments for Childhood OCD
Baltimore, Maryland
The primary purpose of this study is to learn whether personalized assessment of obsessive-compulsive disorder (OCD) symptoms in childhood OCD using mobile health technology are feasible and acceptable for youth and parents. The investigators will also examine whether personalized cognitive-behavioral therapy (CBT) that is informed by personalized OCD assessments yields better clinical outcomes when compared to standard CBT for youth with OCD
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 17
Key Eligibility Criteria
Disqualifiers:Psychotic, Bipolar, Autism, Others
30 Participants Needed
Decision Tool for Arthritis
Durham, North Carolina
This study is an observational study to test and validate a questionnaire and statistical model used to determine patient preferences regarding treatment for any one of 11 musculoskeletal conditions: hip arthritis, knee arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus. This study aims to understand how multiple treatment variables, including pain, rehabilitation time, cost, and choice of surgical versus non-surgical intervention, impact patients' decision-making processes and ultimate choice of treatment.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Inability To Give English Consent
2310 Participants Needed
Neurostimulation + Therapy for Emotional Regulation Issues
Durham, North Carolina
This trial tests a new method that combines teaching emotion management skills with a type of brain stimulation. The goal is to help adults who struggle to calm down when upset and have certain mental health conditions. The brain stimulation aims to make it easier for them to learn and use these skills effectively.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Psychotic Disorder, Bipolar I, Substance Use, Others
Must Not Be Taking:Wellbutrin, Stimulants
240 Participants Needed
Light Therapy for Obsessive-Compulsive Disorder
St. Louis, Missouri
The goal of this clinical trial is to test whether light therapy is effective for reducing symptoms in young adults with OCD and late bedtimes (1am or later). The main question\[s\] it aims to answer are:
Does light therapy reduce OCD symptoms? Does light therapy advance the circadian clock? If there is a comparison group: Researchers will compare a higher dose of light therapy to a lower dose to see if dose amount affects symptom reduction.
Participants will asked to:
1. Wear light therapy glasses for 1 hour each morning and complete a daily light therapy log for 5 weeks
2. Track their sleep every day with a wearable monitor and an electronic sleep diary for 5 weeks
3. Complete a 1-time assessment of sensitivity to light exposure
4. Complete self-report measures of OCD 4 times/day at baseline (2 weeks), mid-treatment (1 week), and end of treatment (1 week)
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 35
Key Eligibility Criteria
Disqualifiers:Night Shift Work, Pregnancy, Nicotine, Others
40 Participants Needed
Exposure and Response Prevention for Obsessive-Compulsive Disorder
Philadelphia, Pennsylvania
This trial studies how hormonal changes during the menstrual cycle affect the effectiveness of a common OCD therapy called Exposure and Response Prevention (EX/RP). Women will undergo therapy at various points in their cycle, and men will also participate for comparison. The goal is to see if timing therapy with hormonal changes can improve outcomes for women with OCD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Key Eligibility Criteria
Disqualifiers:Birth Control, Pregnancy, Neurologic Conditions, Others
Must Not Be Taking:Psychotropic Medications
120 Participants Needed
Deep Brain Stimulation for Obsessive-Compulsive Disorder
Philadelphia, Pennsylvania
This trial tests a device that sends electrical signals to the brain in patients with severe OCD who don't respond to usual treatments. The electrical pulses aim to help control OCD symptoms. This experimental treatment has shown promising results for severe OCD.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 75
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Eating Disorders, Others
Must Be Taking:SSRIs, Antipsychotics, Clomipramine
10 Participants Needed
Cognitive Control Training for Obsessive-Compulsive Disorder
New York, New York
This study aims to examine the effects of a game-like program called cognitive control training (CT) for children with obsessive compulsive disorder (OCD). Children enrolled in this study will receive 4 weeks of the at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games to engage cognitive control processes. Children will complete the NIH Toolbox prior to, mid (2-weeks), and post-CT (4-weeks). Participants will complete MRI scans pre- and post-CT and then be offered a 12-week course of gold-standard Cognitive behavioral therapy with exposure and response prevention (or community referrals) after CT. The long-term goal of this study is to test how this CT intervention may enhance cognitive control capacity to reduce symptoms and improve response to cognitive behavioral therapy with exposure and response prevention in children with OCD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 12
Key Eligibility Criteria
Disqualifiers:Major Depression, PTSD, Bipolar, Others
Must Not Be Taking:Psychotropics
60 Participants Needed
Deep Brain Stimulation for Obsessive-Compulsive Disorder
New York, New York
This trial uses a technique called deep brain stimulation (DBS) to help people with severe OCD who haven't improved with other treatments. Electrodes are placed in a specific brain area to send electrical impulses that adjust brain activity and reduce symptoms. The study aims to personalize the stimulation for each patient to maximize benefits.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Neurological Disorder, Unstable Medical Illness, Psychosis, Substance Abuse, Others
Must Be Taking:SSRIs, Clomipramine, Augmentation Agents
20 Participants Needed
Celecoxib for Obsessive-Compulsive Disorder
New York, New York
This trial tests if adding the anti-inflammatory drug celecoxib to current treatments helps adults with OCD who still have symptoms. It focuses on patients with high brain inflammation, measured by scans and blood tests, to see if they improve more with this added medication. Celecoxib has been tested as an additional therapy in schizophrenia, showing significant improvement in symptoms, particularly in patients with recent-onset schizophrenia.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Suicidality, Neurological Conditions, Others
Must Be Taking:Psychiatric Medications
21 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Ocd clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Ocd clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Ocd trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Ocd is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Ocd medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Ocd clinical trials?
Most recently, we added Transcranial Direct Current Stimulation for OCD, Deep Brain Stimulation for Obsessive-Compulsive Disorder and Virtual Reality for OCD to the Power online platform.
Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.